CDKN2A and breast carcinoma: While ERα is the primary oncogenic driver in ER+ breast cancer cancers, other genetic alterations such as cyclin D1 overexpression in 50% of breast cancers (Fig. 3a) and CDKN2A loss, contribute to disease progression and therapeutic response.